CN116283761A - 3-alkenyl ketone substituted quinoline-2-ketone and green synthesis method thereof - Google Patents
3-alkenyl ketone substituted quinoline-2-ketone and green synthesis method thereof Download PDFInfo
- Publication number
- CN116283761A CN116283761A CN202310090527.7A CN202310090527A CN116283761A CN 116283761 A CN116283761 A CN 116283761A CN 202310090527 A CN202310090527 A CN 202310090527A CN 116283761 A CN116283761 A CN 116283761A
- Authority
- CN
- China
- Prior art keywords
- ketone
- substituted quinoline
- alkenyl
- compound
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000001308 synthesis method Methods 0.000 title claims abstract description 12
- NSYSSMYQPLSPOD-UHFFFAOYSA-N triacetate lactone Chemical compound CC1=CC(O)=CC(=O)O1 NSYSSMYQPLSPOD-UHFFFAOYSA-N 0.000 claims abstract description 36
- 238000000034 method Methods 0.000 claims abstract description 16
- -1 anthranilaldehyde compound Chemical class 0.000 claims abstract description 14
- 230000000975 bioactive effect Effects 0.000 claims abstract description 9
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 5
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 5
- 150000002367 halogens Chemical class 0.000 claims abstract description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 5
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims abstract description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 5
- 230000002194 synthesizing effect Effects 0.000 claims abstract description 3
- 238000006243 chemical reaction Methods 0.000 claims description 31
- 239000002904 solvent Substances 0.000 claims description 14
- 239000003054 catalyst Substances 0.000 claims description 8
- 238000003786 synthesis reaction Methods 0.000 claims description 8
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical class C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 3
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 2
- 238000010189 synthetic method Methods 0.000 claims 2
- 239000007848 Bronsted acid Substances 0.000 claims 1
- 239000002841 Lewis acid Substances 0.000 claims 1
- 150000007517 lewis acids Chemical class 0.000 claims 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 1
- 230000004071 biological effect Effects 0.000 abstract description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 239000002994 raw material Substances 0.000 description 15
- 239000000047 product Substances 0.000 description 12
- 239000000126 substance Substances 0.000 description 9
- 230000008569 process Effects 0.000 description 6
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical class NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 150000002085 enols Chemical class 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 150000002466 imines Chemical class 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000005580 one pot reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- VTESCYNPUGSWKG-UHFFFAOYSA-N (4-tert-butylphenyl)hydrazine;hydrochloride Chemical compound [Cl-].CC(C)(C)C1=CC=C(N[NH3+])C=C1 VTESCYNPUGSWKG-UHFFFAOYSA-N 0.000 description 1
- FXWFZIRWWNPPOV-UHFFFAOYSA-N 2-aminobenzaldehyde Chemical compound NC1=CC=CC=C1C=O FXWFZIRWWNPPOV-UHFFFAOYSA-N 0.000 description 1
- TZOYXRMEFDYWDQ-UHFFFAOYSA-N 3,4-dihydro-1h-quinolin-2-one Chemical group C1=CC=C2NC(=O)CCC2=C1 TZOYXRMEFDYWDQ-UHFFFAOYSA-N 0.000 description 1
- CMRRNGKKEKUHQO-UHFFFAOYSA-N 3-benzoyl-3,4-dihydro-1H-quinolin-2-one Chemical group C(C1=CC=CC=C1)(=O)C1C(NC2=CC=CC=C2C1)=O CMRRNGKKEKUHQO-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000006000 Knoevenagel condensation reaction Methods 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- ALLWOAVDORUJLA-UHFFFAOYSA-N Rebamipida Chemical compound C=1C(=O)NC2=CC=CC=C2C=1CC(C(=O)O)NC(=O)C1=CC=C(Cl)C=C1 ALLWOAVDORUJLA-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 229960004372 aripiprazole Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 229940127236 atypical antipsychotics Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000020335 dealkylation Effects 0.000 description 1
- 238000006900 dealkylation reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- FGRVOLIFQGXPCT-UHFFFAOYSA-L dipotassium;dioxido-oxo-sulfanylidene-$l^{6}-sulfane Chemical compound [K+].[K+].[O-]S([O-])(=O)=S FGRVOLIFQGXPCT-UHFFFAOYSA-L 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 125000006575 electron-withdrawing group Chemical group 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000012450 pharmaceutical intermediate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 229950004535 rebamipide Drugs 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention discloses a 3-alkenyl ketone substituted quinoline-2-ketone skeleton with biological activity and a green synthesis method thereof. The invention provides a structure of a 3-alkenyl ketone substituted quinoline-2-ketone bioactive framework. The structural formula of the 3-alkenyl ketone substituted quinoline-2-ketone bioactive framework is as follows:wherein R is 2 Is any one of ethyl and n-propyl; r is R 3 Is any one of hydrogen atom, alkyl, halogen, trifluoromethyl and cyano. The invention provides a synthesis method thereof, which comprises the following steps: reacting an anthranilaldehyde compound with 4-hydroxy-6-methyl-2-pyrone under a certain condition to prepare the 3-alkenyl ketone substituted quinoline-2-ketone compound. The invention provides a method for synthesizing 3-alkenyl ketone substituted quinoline-2-ketone compounds with various structures.
Description
Technical Field
The invention relates to the technical field of pharmaceutical intermediates and chemical synthesis, in particular to a 3-alkenyl ketone substituted quinoline-2-ketone structure with bioactivity and a green synthesis method thereof.
Background
The quinoline-2-ketone and the derivative thereof are important heterocyclic compounds, have good biological activity, are widely applied in the field of medicine, and play an important role in the treatment of diseases such as cancer, atherosclerosis, schizophrenia, parkinson, alzheimer disease and the like. For example, aripiprazole is a novel atypical antipsychotic marketed in the united states in 2002 for the treatment of schizophrenia; rebamipide plays an important role in promoting regeneration of mucosal tissue, reducing tissue inflammatory reaction, enhancing mucosal barrier function, etc., and is a novel antiulcer agent marketed in japan in 1990; tipirfenib is a novel antitumor drug which can be used for treating myeloma and other cancers, and enters into clinical research of III phase in the United states at present, and the drugs are all quinoline-2-ketone derivatives. In view of the importance of the quinolin-2-one skeleton in the medical field, it is important to efficiently construct quinolin-2-one, especially a multi-functional substituted quinolin-2-one skeleton.
In 2014, the professor "shouyin plum" of the university of Henan industry used benzoyl formic acid and alkenyl amide as raw materials and silver nitrate as a catalyst, and constructed a 3, 4-dihydro-3-benzoyl-2 (1H) -quinolinone backbone by free radical reaction (J.org.chem., 2014,79,8094-8102). However, the reaction requires 2 equivalents of potassium thiosulfate as the oxidizing agent and requires a high temperature of 100 degrees to be carried out.
In 2019, luo Feixian, a national university institute of life and environmental sciences, reports that transition metal Pd/Cu synergistically catalyzes the aryl and intramolecular amination reaction of tandem hydrocarbon bonds, and a one-pot method is used to synthesize a 3, 4-dihydro-2 (1H) -quinolinone skeleton (Org. Lett.,2019,21,1668-1671). The reaction requires not only a relatively expensive metal catalyst, but also a reaction at 140 degrees.
Although the above reactions can synthesize quinolin-2-one frameworks with high efficiency, expensive metal catalysts or high temperature reaction conditions greatly limit the application of these reactions, especially limiting the further industrialization of pharmaceutical manufacturing enterprises.
Therefore, how to use cheap and easily available raw materials, green and mild reaction conditions to efficiently construct the quinoline-2-ketone skeleton, solves the problems existing in the current organic synthesis method, and synthesizes a series of quinoline-2-ketone derivatives is the problem to be solved at present.
Disclosure of Invention
The invention aims at overcoming the defects of the prior art and provides a 3-alkenyl ketone substituted quinoline-2-ketone structure with bioactivity and a green synthesis method thereof. The novel 3-alkenyl ketone substituted quinoline-2-ketone bioactive skeleton provided by the invention provides a novel model molecule for drug development. The synthesis method of the 3-alkenyl ketone substituted quinoline-2-ketone bioactive framework is based on the hydrogen migration process, the framework is efficiently synthesized in one step, the operation is simple, the efficiency is high, the practicability is high, the constructed framework contains various functional groups, and the later synthesis application of the framework is facilitated.
The technical scheme of the invention is realized as follows:
the 3-alkenyl ketone substituted quinoline-2-ketone bioactive framework has the structural formula shown as follows:
wherein R is 1 ,R 2 Is any one of ethyl and n-propyl; r is R 3 Is any one of hydrogen atom, alkyl, halogen, trifluoromethyl and cyano.
The compounds of the present invention may exist in the form of one or more stereoisomers. The various isomers include tautomers, geometric isomers, enantiomers, diastereomers and the like. These isomers and mixtures of these isomers are all within the scope of the present invention.
The invention also provides a synthesis method of the 3-alkenyl ketone substituted quinoline-2-ketone bioactive framework, and a synthetic process route diagram of the invention is shown in figure 1, and the synthesis method comprises the following steps:
uniformly mixing an anthranilate compound and 4-hydroxy-6-methyl-2-pyrone in a solvent, and reacting at 100-120 ℃ to prepare a 3-alkenyl ketone substituted quinoline-2-ketone compound;
wherein, the structural formula of the o-aminobenzaldehyde compound is shown as follows:
wherein R is 1 ,R 2 Is any one of ethyl and n-propyl; r is R 3 Is any one of hydrogen atom, alkyl, halogen, trifluoromethyl and cyano.
Wherein the structural formula of the 4-hydroxy-6-methyl-2-pyrone is as follows:
the reaction condition can be detected by thin layer chromatography, and the purification is carried out after the reaction is finished, so as to obtain the purified product of the 3-alkenyl ketone substituted quinoline-2-ketone compound.
The reaction process specifically comprises the following steps:
o-aminobenzaldehyde compound and 4-hydroxy-6-methyl-2-pyrone are subjected to Knoevenagel condensation reaction to form intermediate product electron-deficient olefin, the electron-deficient olefin is used as driving force to initiate intramolecular hydrogen migration to form an imine intermediate, then the imine intermediate containing amino and lactone is generated through dealkylation in the process of imine hydrolysis, and finally the final product 3-alkenyl ketone substituted quinoline-2-ketone is generated through intramolecular acylation reaction. The synthetic route is specifically as follows:
preferably, the synthesis process as described above is carried out at 120 ℃.
Preferably, the solvent used in the above reaction is green and pollution-free water. The solvent is used in the following amount: 10-20L of solvent is added to each mole of o-aminobenzaldehyde compound.
Preferably, the synthesis reaction does not adopt a catalyst, so that the product synthesis cost is effectively reduced.
The compounds of the present invention may exist in the form of one or more stereoisomers. The various isomers include geometric isomers. These isomers, including mixtures of these isomers, are within the scope of the present invention.
The beneficial effects of the invention are as follows:
1. according to the invention, under mild reaction conditions, the 3-alkenyl ketone substituted quinoline-2-ketone skeleton is efficiently synthesized by one-step reaction, and the technical scheme of the invention provides a convenient and concise synthesis method for the 3-alkenyl ketone substituted quinoline-2-ketone skeleton, so that the 3-alkenyl ketone substituted quinoline-2-ketone skeleton is efficiently constructed through a hydrogen migration process for the first time.
2. The invention develops a method for efficiently synthesizing 3-alkenyl ketone substituted quinoline-2-ketone compounds with multiple functional groups and multiple structures, provides a compound library with multiple structures and 3-alkenyl ketone substituted quinoline-2-ketone frameworks, and provides a novel model molecule for drug development.
3. The method has mild reaction conditions, the 3-alkenyl ketone substituted quinoline-2-ketone compound is synthesized in water through one-step reaction, the substrate universality is good, the substrate substituent can be an electron-withdrawing group or an electron-donating group, and the position of the substituent has no obvious influence on the reaction yield. The invention provides experimental basis for the efficient construction of 3-alkenyl ketone substituted quinoline-2-ketone skeleton with good biological activity, and has good practical significance and application value.
Drawings
FIG. 1 is a synthetic process scheme of the present invention.
Detailed Description
The following description of the embodiments of the present invention will clearly and fully describe the technical solutions of the embodiments of the present invention, and it is apparent that the described embodiments are only some embodiments of the present invention, not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. The term "and/or" as used in this specification includes any and all combinations of one or more of the associated listed items.
The experimental methods used in the following examples are all conventional methods unless otherwise specified; reagents, materials, instruments, etc. used in the examples described below are all commercially available unless otherwise specified; the reaction vessel used in the examples below was a 25mL thick-walled pressure-resistant tube.
Example 1
The embodiment provides a synthesis method of a 3-alkenyl ketone substituted quinoline-2-ketone bioactive framework, which comprises the following steps:
taking 0.1mmol of N-diethyl substituted o-aminobenzaldehyde compound in a reaction tube, sequentially adding 1mL of solvent, adding 0.12mmol of 4-hydroxy-6-methyl-2-pyrone, controlling the reaction temperature of the system, continuously stirring, and carrying out sample application tracking reaction through a thin layer chromatography plate until the raw materials are completely reacted. After the reaction is completed, separating and purifying by using a silica gel column, and rotary steaming the purified product to obtain a target product. The reaction formula is as follows:
2. according to the method, the following 10 parallel test groups are set, and different reaction conditions are respectively adopted, such as: different raw material proportions, different solvents, different solvent volumes, different temperatures. The specific settings for the different test groups are shown in Table 1:
TABLE 1 reaction yield of anthranilaldehyde with 4-hydroxy-6-methyl-2-pyruvic ketone under different conditions
From the above analysis of parallel test results, it can be seen that: when water is used as a solvent in the synthesis reaction, 10-20L of the solvent is added per mol of the o-aminobenzaldehyde compound, and the reaction can be carried out; when 10L of water is added to each mole of o-aminobenzaldehyde compound, the yield is highest; the reaction temperature is 120 ℃, and the yield is the highest. In addition, under the optimal reaction conditions, 30% of acetic acid or triethylamine is added as a catalyst in the reaction, the reaction yield is low,
in the following examples 2 to 10, reactions were carried out according to the procedure of example 1; in the reaction system, raw materials of o-aminobenzaldehyde compound and 4-hydroxy-6-methyl-2-pyrone are respectively 0.1mmol and 0.12mmol, water is used as a solvent, and the reaction is continuously stirred at 120 ℃ until the raw materials are completely reacted, so that corresponding target products are respectively obtained.
Example 2
Raw materials: n-diethyl-substituted anthranilic acid, 4-hydroxy-6-methyl-2-pyrone
The product is: the chemical formula: c (C) 15 H 17 NO 3
Molecular weight: 259.1208
yield: 85%
1 H NMR(500MHz,CDCl 3 )δ15.04(s,1H),7.22–7.17(m,1H),7.13(t,J=7.2Hz,1H),6.96(dd,J=13.4,7.0Hz,2H),5.57(s,1H),4.02–3.87(m,2H),3.46(t,J=6.8Hz,1H),3.25(dd,J=15.6,7.7Hz,1H),2.97(dd,J=15.6,5.8Hz,1H),1.95(s,3H),1.21(dd,J=15.8,7.9Hz,3H). 13 C NMR(125MHz,CDCl 3 )δ191.5,188.5,166.9,138.6,128.4,127.8,124.7,123.2,114.7,99.8,50.7,37.9,28.2,23.9,12.6.HRMS(ESI)m/z:[M+Na] + calcd.for C 15 H 17 NNaO 3 :282.1101,found:282.1097.
Example 3
Raw materials: N-di-N-propyl substituted anthranilic acid, 4-hydroxy-6-methyl-2-pyrone
The product is: the chemical formula: c (C) 16 H 19 NO 3
Molecular weight: 273.1365
yield: 65%
1 H NMR(500MHz,CDCl 3 )δ15.09(s,1H),7.24(d,J=7.8Hz,1H),7.20(d,J=7.2Hz,1H),7.01(dd,J=19.4,7.7Hz,2H),5.64(s,1H),3.98–3.85(m,2H),3.55(t,J=6.5Hz,1H),3.31(dt,J=16.2,8.2Hz,1H),3.04(dd,J=15.6,5.7Hz,1H),2.02(s,3H),1.69(dt,J=15.6,7.7Hz,2H),0.97(t,J=7.7Hz,3H). 13 CNMR(125MHz,CDCl 3 )δ191.6,188.3,167.1,138.7,128.4,127.7,124.8,123.2,114.9,99.8,50.8,44.3,28.2,23.9,20.4,11.3.HRMS(ESI)m/z:[M+H] + calcd.for C 16 H 20 NO 3 :274.1438,found:274.1434.
Example 4
Raw materials: n, N-diethyl-2-amino-6-fluorobenzaldehyde, 4-hydroxy-6-methyl-2-pyrone
The product is: the chemical formula: c (C) 15 H 16 FNO 3
Molecular weight: 277.1114
yield: 63%
1 H NMR(500MHz,CDCl 3 )δ15.04(s,1H),7.21(dd,J=14.8,7.3Hz,1H),6.80(t,J=8.7Hz,2H),5.66(s,1H),4.00(m,2H),3.55(t,J=6.2Hz,1H),3.40(dd,J=16.1,7.0Hz,1H),3.02(dd,J=16.1,5.6Hz,1H),2.03(s,3H),1.27(d,J=7.7Hz,3H). 13 C NMR(125MHz,CDCl 3 )δ191.4,188.2,166.5,160.0(d,J=242.5Hz),140.34(d,J=6.4Hz),128.44(d,J=9.5Hz),112.1(d,J=21.3Hz),110.3(d,J=8.8Hz),110.2(d,J=11.2Hz),99.6,49.9,38.3,23.8,20.4(d,J=4.1Hz),12.6.HRMS(ESI)m/z:[M+Na] + calcd.for C 15 H 16 FNNaO 3 :300.1006,found:300.1006.
Example 5
Raw materials: n, N-diethyl-2-amino-6-bromobenzaldehyde, 4-hydroxy-6-methyl-2-pyrone
The product is: the chemical formula: c (C) 15 H 16 BrNO 3
Molecular weight: 337.0314
yield: 60 percent of
1 H NMR(500MHz,CDCl 3 )δ15.02(s,1H),7.27(s,1H),7.12(t,J=7.7Hz,1H),6.97(d,J=7.9Hz,1H),5.66(s,1H),3.99(m,2H),3.61–3.47(m,2H),3.14(d,J=12.9Hz,1H),2.03(s,3H),1.30–1.24(m,3H). 13 C NMR(125MHz,CDCl 3 )δ191.2,188.2,166.5,139.9,128.6,127.4,124.8,124.1,114.0,99.7,50.2,38.4,27.9,23.9,12.6.HRMS(ESI)m/z:[M+H] + calcd.for C 15 H 17 BrNO 3 :338.0386,found:338.0389.
Example 6
Raw materials: n, N-diethyl-2-amino-4-chlorobenzaldehyde, 4-hydroxy-6-methyl-2-pyrone
The product is: the chemical formula: c (C) 15 H 16 ClNO 3
Molecular weight: 293.0819
yield: 50 percent of
1 H NMR(500MHz,CDCl 3 )δ15.05(s,1H),7.12(d,J=7.7Hz,1H),6.99(s,2H),5.63(s,1H),3.98(m,2H),3.54(s,1H),3.29(dd,J=15.5,6.0Hz,1H),3.02(dd,J=15.6,4.3Hz,1H),2.03(s,3H),1.29(t,J=7.1Hz,3H). 13 C NMR(125MHz,CDCl 3 )δ191.3,188.3,166.7,139.7,133.4,129.4,123.1,123.0,115.0,99.6,50.5,38.1,27.6,23.8,12.5.HRMS(ESI)m/z:[M+H] + calcd.for C 15 H 17 ClNO 3 :294.0891,found:294.0895.
Example 7
Raw materials: n, N-diethyl-2-amino-4-methylbenzaldehyde, 4-hydroxy-6-methyl-2-pyrone
The product is: the chemical formula: c (C) 16 H 19 NO 3
Molecular weight: 273.1365
yield: 62 percent of
1 H NMR(500MHz,CDCl 3 )δ15.11(s,1H),7.07(d,J=7.1Hz,1H),6.83(d,J=9.4Hz,2H),5.63(s,1H),3.99(m,2H),3.51(t,J=6.4Hz,1H),3.27(dd,J=15.6,7.4Hz,1H),3.00(dd,J=15.5,5.5Hz,1H),2.36(s,3H),2.02(s,3H),1.29(t,J=7.5Hz,3H). 13 C NMR(125MHz,CDCl 3 )δ191.7,188.5,166.9,138.5,137.6,128.2,123.9,121.6,115.4,99.8,50.9,37.9,27.9,23.9,21.6,12.7.HRMS(ESI)m/z:[M+Na] + calcd.for C 16 H 19 NNaO 3 :296.1257,found:296.1258.
Example 8
Raw materials: n, N-diethyl-2-amino-4-trifluoromethylbenzaldehyde, 4-hydroxy-6-methyl-2-pyrone
The product is: the chemical formula: c (C) 16 H 16 F 3 NO 3
Molecular weight: 327.1082
Yield: 72 percent of
1 H NMR(500MHz,DMSO)δ11.81(s,1H),7.31(dd,J=8.5,1.8Hz,1H),7.24(d,J=2.0Hz,1H),6.60(d,J=8.5Hz,1H),6.08(d,J=0.6Hz,1H),3.46(s,2H),3.13(d,J=7.2Hz,2H),2.19(s,3H),1.23(t,J=7.1Hz,3H). 13 C NMR(125MHz,DMSO)δ167.2,166.1,161.6,149.7,125.9(q,J=268.8Hz),126.4(q,J=3.8Hz),124.8(q,J=3.8Hz),123.7,115.2(q,J=31.3Hz),108.9,100.4,98.8,37.9,25.2,19.8,14.5.HRMS(ESI)m/z:[M+H] + calcd.for C 16 H 17 F 3 NO 3 :328.1155,found:328.1159.
Example 9
Raw materials: n, N-diethyl-2-amino-4-cyanobenzaldehyde, 4-hydroxy-6-methyl-2-pyrone
The product is: the chemical formula: c (C) 16 H 16 N 2 O 3
Molecular weight: 284.1161
Yield: 68%
1 H NMR(500MHz,DMSO)δ11.75(s,1H),7.06(d,J=7.7Hz,1H),6.90(dd,J=7.6,1.2Hz,1H),6.80(s,1H),6.08(s,1H),3.45(s,2H),3.11(q,J=7.1Hz,2H),2.19(s,3H),1.22(t,J=7.1Hz,3H). 13 C NMR(125MHz,DMSO)δ167.2,165.9,161.6,147.3,130.1,129.5,120.4,119.4,111.6,109.9,100.4,98.3,37.9,25.5,19.8,14.4.HRMS(ESI)m/z:[M+H] + calcd.for C 16 H 17 N 2 O 3 :285.1234,found:285.1222.
Example 10
Raw materials: n, N-diethyl-2-amino-5-cyanobenzaldehyde, 4-hydroxy-6-methyl-2-pyrone
The product is: the chemical formula: c (C) 16 H 16 N 2 O 3
Molecular weight: 284.1161
Yield: 67%
1 H NMR(500MHz,DMSO)δ11.83(s,1H),7.41(dd,J=8.5,2.1Hz,1H),7.19(d,J=2.0Hz,1H),6.58(d,J=8.6Hz,1H),6.09(s,1H),3.41(s,2H),3.16(q,J=7.1Hz,2H),2.20(s,3H),1.22(t,J=7.2Hz,3H). 13 C NMR(125MHz,DMSO)δ167.3,165.9,161.8,150.3,132.7,132.3,124.1,121.3,109.5,100.4,98.3,95.8,37.7,25.0,19.8,14.4.HRMS(ESI)m/z:[M+H] + calcd.for C 16 H 17 N 2 O 3 :285.1234,found:285.1226.
The foregoing description of the preferred embodiments of the invention is not intended to be limiting, but rather is intended to cover all modifications, equivalents, alternatives, and improvements that fall within the spirit and scope of the invention.
Claims (7)
- 2. The method for synthesizing the 3-alkenyl ketone substituted quinoline-2-one bioactive skeleton according to claim 1, comprising the following steps:uniformly mixing an anthranilate compound and 4-hydroxy-6-methyl-2-pyrone in a solvent, and reacting at 100-120 ℃ to prepare a 3-alkenyl ketone substituted quinoline-2-ketone compound;wherein, the structural formula of the o-aminobenzaldehyde compound is shown as follows:wherein R is 1 ,R 2 Is any one of ethyl and n-propyl; r is R 3 Is any one of hydrogen atom, alkyl, halogen, trifluoromethyl and cyano.Wherein the structural formula of the 4-hydroxy-6-methyl-2-pyrone is as follows:
- 3. the synthetic method of claim 2 wherein the solvent is water, acetonitrile or tetrahydrofuran.
- 4. The synthesis method according to claim 2, wherein the molar ratio of the anthranilate compound to 4-hydroxy-6-methyl-2-pyrone is 1: (1-5).
- 5. The method of synthesis according to claim 2, wherein the solvent is used in an amount of: 10-20L of solvent is added to each mole of o-aminobenzaldehyde compound.
- 6. The synthetic method of claim 2 wherein the catalyst is added prior to the reaction, the catalyst being a bronsted or lewis acid.
- 7. The method according to claim 2 or 6, wherein the catalyst is used in an amount of 5 to 50mol%.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310090527.7A CN116283761B (en) | 2023-02-02 | 2023-02-02 | 3-Alkenyl ketone substituted quinoline-2-ketone and green synthesis method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310090527.7A CN116283761B (en) | 2023-02-02 | 2023-02-02 | 3-Alkenyl ketone substituted quinoline-2-ketone and green synthesis method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116283761A true CN116283761A (en) | 2023-06-23 |
CN116283761B CN116283761B (en) | 2024-06-28 |
Family
ID=86777093
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310090527.7A Active CN116283761B (en) | 2023-02-02 | 2023-02-02 | 3-Alkenyl ketone substituted quinoline-2-ketone and green synthesis method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116283761B (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5972961A (en) * | 1997-08-28 | 1999-10-26 | Bristol-Myers Squibb Company | 4-aryl-3-aminoquinoline-2-one derivatives as potassium channel modulators |
CN113651813A (en) * | 2021-08-30 | 2021-11-16 | 山东瀚华工程设计有限公司 | 2, 3-dihydroquinoline-4-ketone bioactive skeleton and synthesis method and application thereof |
-
2023
- 2023-02-02 CN CN202310090527.7A patent/CN116283761B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5972961A (en) * | 1997-08-28 | 1999-10-26 | Bristol-Myers Squibb Company | 4-aryl-3-aminoquinoline-2-one derivatives as potassium channel modulators |
CN113651813A (en) * | 2021-08-30 | 2021-11-16 | 山东瀚华工程设计有限公司 | 2, 3-dihydroquinoline-4-ketone bioactive skeleton and synthesis method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN116283761B (en) | 2024-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110143918B (en) | 3, 4-dihydro-3- (2-hydroxybenzoyl) -2(1H) -quinolinone active skeleton, synthetic method and application | |
CN111675662B (en) | Preparation method of 2-trifluoromethyl substituted quinazolinone compound | |
CN114539252A (en) | 2, 3-dihydroquinoline-4-ketone bioactive skeleton and synthesis method and application thereof | |
CN116283761B (en) | 3-Alkenyl ketone substituted quinoline-2-ketone and green synthesis method thereof | |
CN115477627B (en) | Polysubstituted 2-furanone compound and synthesis method thereof | |
CN106749235B (en) | The preparation method of poly-substituted quinoline and azole derivatives | |
JPH01221374A (en) | Production of 4-oxo-1-benzopyran-2-carboxylic acid derivative having optical activity, intermediate for synthesizing said derivative and production of said intermediate | |
CN105820174A (en) | Polysubstituted thienoindole derivative and preparation method thereof | |
CN113636968B (en) | Synthetic method of 3-acyl pyrrole compound | |
CN104788396A (en) | Preparation method of N-substituted oxazolone polymer derivatives | |
CN115974781B (en) | Green synthesis method of beta-amino acid derivative active framework | |
CN115403588A (en) | Oxoindolspirodibenz [ b, f ] oxooctanes and preparation method thereof | |
CN112500419A (en) | Epoxy fused 2-methylene pyrrolidine compound and preparation method thereof | |
CN113429409A (en) | Sulfur-containing polysubstituted indolizine compound and preparation method thereof | |
CN111471041B (en) | Synthetic method of oxazolidinone antibacterial drug intermediate | |
CN109748809B (en) | Method for synthesizing 2-substituted amino-1, 4-naphthoquinone derivative | |
CN107188909B (en) | Method for synthesizing indole-substituted or ferrocene-substituted azaarene | |
CN117185999A (en) | Green synthesis method of 3, 4-dihydro-2 (1H) -quinolinone bioactive framework | |
CN111892582B (en) | Preparation method of benzofuran coumarin compound | |
CN114634427B (en) | Preparation method of indeno polycyclic compound containing spiro | |
CN113845481B (en) | Synthesis method of 4, 4-dimethyl-4, 5-dihydropyridazin-3-one | |
CN116444534A (en) | Fluoroalcohol-promoted [5+1] dearomatization reaction | |
CN110467613B (en) | Reaction method for alkylation of imide cation intramolecular amide by nickel catalysis | |
CN116003369A (en) | 3-spirohexenone substituted chroman structure and synthesis method thereof | |
CN114605437A (en) | Synthesis process for preparing three telaprevir medicaments by continuous one-pot method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |